158 related articles for article (PubMed ID: 19337444)
21. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma.
Terpos E; Palermos J; Tsionos K; Anargyrou K; Viniou N; Papassavas P; Meletis J; Yataganas X
Eur J Haematol; 2000 Nov; 65(5):331-6. PubMed ID: 11092464
[TBL] [Abstract][Full Text] [Related]
22. Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment.
Terpos E; Palermos J; Viniou N; Vaiopoulos G; Meletis J; Yataganas X
Calcif Tissue Int; 2001 May; 68(5):285-90. PubMed ID: 11683535
[TBL] [Abstract][Full Text] [Related]
23. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
24. Use of Pamidronate for Hypercalcemia of Malignancy in Renal Dysfunction.
Norman SJ; Reeves DJ; Saum LM
J Pharm Pract; 2021 Aug; 34(4):553-557. PubMed ID: 31648595
[TBL] [Abstract][Full Text] [Related]
25. Metabolic effects of pamidronate in patients with metastatic bone disease.
Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
Br J Cancer; 1996 May; 73(9):1089-95. PubMed ID: 8624269
[TBL] [Abstract][Full Text] [Related]
26. Dosing regimens and main adverse events of bisphosphonates.
Body JJ
Semin Oncol; 2001 Aug; 28(4 Suppl 11):49-53. PubMed ID: 11544576
[TBL] [Abstract][Full Text] [Related]
27. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.
Berenson JR; Hillner BE; Kyle RA; Anderson K; Lipton A; Yee GC; Biermann JS;
J Clin Oncol; 2002 Sep; 20(17):3719-36. PubMed ID: 12202673
[TBL] [Abstract][Full Text] [Related]
28. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
[TBL] [Abstract][Full Text] [Related]
29. Bisphosphonates and breast carcinoma.
Lipton A
Cancer; 1997 Oct; 80(8 Suppl):1668-73. PubMed ID: 9362434
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
Hortobagyi GN; Theriault RL; Porter L; Blayney D; Lipton A; Sinoff C; Wheeler H; Simeone JF; Seaman J; Knight RD
N Engl J Med; 1996 Dec; 335(24):1785-91. PubMed ID: 8965890
[TBL] [Abstract][Full Text] [Related]
31. Effect of a convenient single 90-mg pamidronate dose on biochemical markers of bone metabolism in patients with acute spinal cord injury.
Mechanick JI; Liu K; Nierman DM; Stein A
J Spinal Cord Med; 2006; 29(4):406-12. PubMed ID: 17044392
[TBL] [Abstract][Full Text] [Related]
32. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
Body JJ; Greipp P; Coleman RE; Facon T; Geurs F; Fermand JP; Harousseau JL; Lipton A; Mariette X; Williams CD; Nakanishi A; Holloway D; Martin SW; Dunstan CR; Bekker PJ
Cancer; 2003 Feb; 97(3 Suppl):887-92. PubMed ID: 12548591
[TBL] [Abstract][Full Text] [Related]
33. Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma.
Gordon S; Helfrich MH; Sati HI; Greaves M; Ralston SH; Culligan DJ; Soutar RL; Rogers MJ
Br J Haematol; 2002 Nov; 119(2):475-83. PubMed ID: 12406088
[TBL] [Abstract][Full Text] [Related]
34. Patients' experience of ambulatory self-administration of pamidronate in multiple myeloma.
Johansson E; Langius-Eklöf A; Engervall P; Wredling R
Cancer Nurs; 2005; 28(2):158-65. PubMed ID: 15815186
[TBL] [Abstract][Full Text] [Related]
35. Pamidronate therapy as prevention of bone loss following renal transplantation.
Fan SL; Almond MK; Ball E; Evans K; Cunningham J
Kidney Int; 2000 Feb; 57(2):684-90. PubMed ID: 10652047
[TBL] [Abstract][Full Text] [Related]
36. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
[TBL] [Abstract][Full Text] [Related]
37. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.
Barrett-Lee P; Bloomfield D; Dougherty L; Harries M; Laing R; Patel H; Walker M
Curr Med Res Opin; 2007 Jul; 23(7):1575-82. PubMed ID: 17559749
[TBL] [Abstract][Full Text] [Related]
38. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.
Coukell AJ; Markham A
Drugs Aging; 1998 Feb; 12(2):149-68. PubMed ID: 9509293
[TBL] [Abstract][Full Text] [Related]
39. The role of disodium pamidronate in the management of bone pain due to malignancy.
Groff L; Zecca E; De Conno F; Brunelli C; Boffi R; Panzeri C; Cazzaniga M; Ripamonti C
Palliat Med; 2001 Jul; 15(4):297-307. PubMed ID: 12054147
[TBL] [Abstract][Full Text] [Related]
40. Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest.
Watanabe Y; Ohshima H; Mizuno K; Sekiguchi C; Fukunaga M; Kohri K; Rittweger J; Felsenberg D; Matsumoto T; Nakamura T
J Bone Miner Res; 2004 Nov; 19(11):1771-8. PubMed ID: 15476576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
